Tag: Amyloidosis treatment

In a significant development for patients with a specific type of amyloidosis, recent FDA approvals have provided new and transformative options for treatment. This includes new drugs to treat amyloidosis, specifically targeting transthyretin-mediated cardiac amyloidosis (ATTR-CM) with different mechanisms of action.

Over the last decade, there has been a significant expansion in the number of FDA-approved drugs for amyloidosis, with distinct treatments now available for different types of the disease. The answer to **What drugs are FDA approved for amyloidosis?** depends on whether a patient has transthyretin (ATTR) or light chain (AL) amyloidosis, as the treatments for each type differ substantially.